GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. / Knudsen, L.B.; Agerso, H.; Bjenning, C.; Holst, J.J.

In: Drug Future, No. 26, 2001, p. 677-685.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Knudsen, LB, Agerso, H, Bjenning, C & Holst, JJ 2001, 'GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development', Drug Future, no. 26, pp. 677-685.

APA

Knudsen, L. B., Agerso, H., Bjenning, C., & Holst, J. J. (2001). GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drug Future, (26), 677-685.

Vancouver

Knudsen LB, Agerso H, Bjenning C, Holst JJ. GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drug Future. 2001;(26):677-685.

Author

Knudsen, L.B. ; Agerso, H. ; Bjenning, C. ; Holst, J.J. / GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. In: Drug Future. 2001 ; No. 26. pp. 677-685.

Bibtex

@article{91cf56c074c711dbbee902004c4f4f50,
title = "GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development",
author = "L.B. Knudsen and H. Agerso and C. Bjenning and J.J. Holst",
year = "2001",
language = "English",
pages = "677--685",
journal = "Drug Future",
number = "26",

}

RIS

TY - JOUR

T1 - GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development

AU - Knudsen, L.B.

AU - Agerso, H.

AU - Bjenning, C.

AU - Holst, J.J.

PY - 2001

Y1 - 2001

M3 - Journal article

SP - 677

EP - 685

JO - Drug Future

JF - Drug Future

IS - 26

ER -

ID: 170825